EU member states urged to support the Dutch Presidency’s vision on access to affordable medicines

20 April 2016
eu-european-union-flag

20 civil society associations are urging European Union member states to support the Dutch EU Presidency’s vision on access to affordable medicines. The call for backing comes as Health Ministers meet in Amsterdam this week, according to posting on the website of the European Public Health Alliance.

The joint statement by groups such as the EPHA, BUKO Pharma-Kampagne, Health Action International, Médecins Sans Frontières - Access Campaign and Universities Allied for Essential Medicines – Europe, to name just a few, states the following:

“We strongly support the Dutch European Union (EU) Presidency’s critique of the current over-protection and misuse of intellectual property and related rights for pharmaceuticals, and its goal to better balance the reward for innovation against the assurance of affordability of medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical